Indeed, Ryan Robb et al. found that BRAF inhibitor selectively radiosensitized BRAFV600E thyroid cancer cells through inhibiting NHEJ [50] and Tina Dasgupta et al. demonstrated RT + PLX4720 exhibited greater anti-tumor effects than either monotherapy in BRAFV600E high-grade gliomas [51], suggesting that these combined approaches hold promise and warrants further investigation. Here, BRAF is linked to thyroid gland carcinoma.